AVH (ASX) Enlightenment

Originally posted by Interloping ↑

Here's a summary of key points I took from the conference call:

FDA approval for treatment of both 2^nd and 3^rd degree burns.

USA is largest healthcare and burns treatment market globally

First PMA granted by FDA for burns in over 2 decades

No requirement for further trials – but Avita plans trials anyway

7000 patients treated to date.

Quote from an investment group to avita team: “our team is astounded at the level of data you have compared to others in the burn and wound healing space”

Significant portion of $50 million still to be received from BARDA – funding trials with objective for future procurement; timing to be announced.

500,000 burn treatments annually USA

$5billion a year spent treating burns

Next largest burns market, Germany, only 16% of USA

Economic modelling – using in 2^nd and in combination for 3^rd >44% reduction in costs for large burns. $13 million saving for a 200 bed burns centre using recell.
Avita estimates initial target of USD $200 million market.

Other markets than burns to follow

Prep for launch:

recruitment of sales and marketing leaders with experience in burns;

promotional materials

sales team recruitment to be completed

formally launch Q4 2018

details of launch to be released to market over next 60 days

planned costing per device of $$5,000 to $10,000

1 kit per 10% total body surface area

Clarification of what a “pre-market approval” means – it is a full market approval; this is the type of approval needed when no other device exists on the market that can be compared to

Avita not aware of Renovacare being very active in R&D: only spending about $300,000/year. No real clinical trials in place. [Implication seems to be Renovacare is not seen as being serious about actually getting a product to market]

In the US health system, treatment of burns is paid to hospitals per square cm burns. No specific reimbursement is made for the device costs – so so systems need to be established for reimbursement.

Ongoing investigation of ways to improve the usability of the product (e.g., to require less clinician time to apply treatment)

Cash burn over next 12 months will depend on how aggressively marketing proceeds. Expect to have a better estimate of this over next 60 days

Level of US burn specialist awareness of recell characterised as “High” … “A very big buzz going on in the United States about the availability of ReCell”. First major development in burns care in past 2 decades.

Answering why up-take in areas with existing approval (e.g., Australia, with TGA approval) has been low, answered that this is the first time there has been a body of randomised controlled trials that would be acceptable to physicians to change standards of care. Previously only had case studies; these trials confirm at least equivalent outcomes while cutting treatment costs.

Expand

Great job and thanks so much for the summary. Was going to listen to the call later when I get a moment but it's great to get the bullet points. All sounding very good. Got my first parcel this morning although I wish I had been a little more patient and knocked a few cents off the price Still it will be meaningless in the long run.

No.	Vol.	Price($)
2	3056	$2.62

No.

Vol.

Price($)

3056

$2.62

Price($)	Vol.	No.
$2.63	4999	1

Price($)

Vol.

No.

$2.63

4999

No.	Vol.	Price($)
1	2671	2.620
2	23181	2.580
2	10350	2.560
2	4338	2.550
1	1200	2.500

No.

Vol.

Price($)

2671

2.620

23181

2.580

10350

2.560

4338

2.550

1200

2.500

Price($)	Vol.	No.
2.630	4999	1
2.650	1070	2
2.700	1110	2
2.730	5000	1
2.740	4614	1

Price($)

Vol.

No.

2.630

4999

2.650

1070

2.700

1110

2.730

5000

2.740

4614

(20min delay)
Last $2.63		Change 0.160(6.48%)		Mkt cap ! $179.0M

Open	High	Low	Value	Volume
$2.54	$2.64	$2.54	$874.2K	336.4K

Enlightenment, page-48

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

Immutep reports strong response rate from immunotherapies treating carcinomas

Almonty locks in govt agreement for tungsten oxide plant in South Korea

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Bitcoin investors need to know the risks

Nimy to raise $1.21M to explore 'newsy' WA targets

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Enlightenment, page-48

Top Stories

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

Immutep reports strong response rate from immunotherapies treating carcinomas

Almonty locks in govt agreement for tungsten oxide plant in South Korea

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Bitcoin investors need to know the risks

Nimy to raise $1.21M to explore 'newsy' WA targets

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News